Douglas F Nixon

List of Publications by Year
in descending order

287 papers	19,596 citations	17776 65 h-index	15698 129 g-index
298 all docs	298 docs citations	298 times ranked	20384 citing authors

#	Article	IF	Citations
1	Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. Journal of Biomolecular Structure and Dynamics, 2022, 40, 7367-7380.	2.0	13
2	HIV-1 Exploits Transitions Between CD4⁺ T Cell Migration and Activation. AIDS Research and Human Retroviruses, 2022, 38, 97-99.	0.5	0
3	Heterologous vaccination interventions to reduce pandemic morbidity and mortality: Modeling the US winter 2020 COVID-19 wave. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	19
4	Booster vaccines for COVID-19 vaccine breakthrough cases?. Lancet, The, 2022, 399, 1224.	6.3	1
5	Specific human endogenous retroviruses predict metastatic potential in uveal melanoma. JCI Insight, 2022, 7, .	2.3	5
6	How human endogenous retroviruses interact with the microbiota in health and disease. Trends in Microbiology, 2022, 30, 812-815.	3.5	7
7	Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVIDâ€19 deaths in Italy. Journal of Medical Virology, 2021, 93, 64-65.	2.5	131
8	Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2). Journal of Medical Virology, 2021, 93, 187-189.	2.5	18
9	The Immunologistsâ€™ Guide to Pandemic Preparedness. Trends in Immunology, 2021, 42, 91-93.	2.9	4
10	Genetic risk for severe COVIDâ€19 correlates with lower inflammatory marker levels in a SARSâ€CoVâ€2â€negative cohort. Clinical and Translational Immunology, 2021, 10, e1292.	1.7	4
11	Anticipated reduction in COVID-19 mortality due to population-wide BCG vaccination: evidence from Germany. Human Vaccines and Immunotherapeutics, 2021, 17, 2451-2453.	1.4	14
12	Can existing unrelated vaccines boost a COVID-19 vaccine prime?. EClinicalMedicine, 2021, 32, 100758.	3.2	3
13	Restriction Factor Expression in Vertically Infected Children Living With HIV-1. Pediatric Infectious Disease Journal, 2021, 40, 144-146.	1.1	0
14	Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Science Advances, 2021, 7, .	4.7	100
15	Locus-Specific Characterization of Human Endogenous Retrovirus Expression in Prostate, Breast, and Colon Cancers. Cancer Research, 2021, 81, 3449-3460.	0.4	20
16	Heterologous vaccine interventions: boosting immunity against future pandemics. Molecular Medicine, 2021, 27, 54.	1.9	13
17	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. New England Journal of Medicine, 2021, 385, e7.	13.9	60
18	Next-Generation Human Cerebral Organoids as Powerful Tools To Advance NeuroHIV Research. MBio, 2021, 12, e0068021.	1.8	10

#	Article	IF	Citations
19	Restriction of HIV-1 Infection in Sickle Cell Trait. Blood Advances, 2021, 5, 4922-4934.	2.5	2
20	Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry. Molecular Medicine, 2021, 27, 105.	1.9	18
21	Extreme immunotherapy: emergency immunology to defeat pandemics. Molecular Medicine, 2021, 27, 112.	1.9	0
22	Hallmarks of Retroelement Expression in T-Cells Treated With HDAC Inhibitors. Frontiers in Virology, 2021, 1, .	0.7	5
23	Lithium treatment and human hippocampal neurogenesis. Translational Psychiatry, 2021, 11, 555.	2.4	13
24	SARS-CoV-2 infection mediates differential expression of human endogenous retroviruses and long interspersed nuclear elements. JCI Insight, 2021, 6, .	2.3	26
25	HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing Platform. Molecular Therapy - Methods and Clinical Development, 2020, 16, 11-20.	1.8	16
26	Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV. Molecular Therapy - Methods and Clinical Development, 2020, 19, 78-88.	1.8	10
27	Telomere length and human hippocampal neurogenesis. Neuropsychopharmacology, 2020, 45, 2239-2247.	2.8	25
28	Human Endogenous Retrovirus Expression Is Upregulated in the Breast Cancer Microenvironment of HIV Infected Women: A Pilot Study. Frontiers in Oncology, 2020, 10, 553983.	1.3	11
29	Human Endogenous Retrovirus Expression Is Associated with Head and Neck Cancer and Differential Survival. Viruses, 2020, 12, 956.	1.5	20
30	Involvement of Cisgender and Transgender Individuals in Studies on the Impact of Hormonal Therapy on COVID-19. AIDS Patient Care and STDs, 2020, 34, 367-368.	1.1	8
31	Human Endogenous Retrovirus K in Cancer: A Potential Biomarker and Immunotherapeutic Target. Viruses, 2020, 12, 726.	1.5	55
32	Conditional economic incentives to improve HIV prevention. Lancet HIV,the, 2020, 7, e85.	2.1	1
33	The behavioral, cellular and immune mediators of HIV-1 acquisition: New insights from population genetics. Scientific Reports, 2020, 10, 3304.	1.6	8
34	Comments on â€œcoinfection of SARSâ€CoVâ€2 and HIV in a patient in Wuhan city, Chinaâ€. Journal of Medical Virology, 2020, 92, 1416-1416.	2.5	5
35	Factors associated with attitudes towards HIV cure research among transgender women and travestis: a cross-sectional survey in SÃ£o Paulo, Brazil. BMJ Open, 2020, 10, e040092.	0.8	5
36	MicroRNAs 145 and 148a Are Upregulated During Congenital Zika Virus Infection. ASN Neuro, 2019, 11, 175909141985098.	1.5	24

#	Article	IF	Citations
37	Transcriptomic analysis of human endogenous retroviruses in systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21350-21351.	3.3	13
38	22THE PSYCHIATRIC RISK GENE NT5C2 REGULATES PROTEIN TRANSLATION IN HUMAN NEURAL PROGENITOR CELLS, AND IS INVOLVED IN LOCOMOTOR BEHAVIOUR IN DROSOPHILA MELANOGASTER. European Neuropsychopharmacology, 2019, 29, S1078.	0.3	0
39	Histoarchitectural Deterioration of Lymphoid Tissues in HIV-1 Infection and in Aging. AIDS Research and Human Retroviruses, 2019, 35, 1148-1159.	0.5	15
40	Telescope: Characterization of the retrotranscriptome by accurate estimation of transposable element expression. PLoS Computational Biology, 2019, 15, e1006453.	1.5	99
41	Nef-induced differential gene expression in primary CD4+ T cells following infection with HIV-1 isolates. Virus Genes, 2019, 55, 541-544.	0.7	3
42	The Intimate Relationship Between CD4+ T Cell Morphology and HIV-1 Infection. AIDS Research and Human Retroviruses, 2019, 35, 509-510.	0.5	2
43	Immune Escape of AML Cells after Transplantation. New England Journal of Medicine, 2019, 380, 1289-1290.	13.9	2
44	Addressing the HIV crisis in the Philippines. Lancet Public Health, The, 2019, 4, e126.	4.7	1
45	Recommendations for analytical antiretroviral treatment interruptions in HIV research trialsâ€"report of a consensus meeting. Lancet HIV,the, 2019, 6, e259-e268.	2.1	139
46	The Psychiatric Risk Gene NT5C2 Regulates Adenosine Monophosphate-Activated Protein Kinase Signaling and Protein Translation in Human Neural Progenitor Cells. Biological Psychiatry, 2019, 86, 120-130.	0.7	42
47	Short Communication: Expression of Host Restriction Factors by Memory CD4+ T Cells Differs Between Healthy Donors and HIV-1-Infected Individuals with Effective Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2019, 35, 108-111.	0.5	3
48	Allogeneic BK Virusâ€"Specific T Cells for PML. New England Journal of Medicine, 2019, 380, 105-106.	13.9	1
49	IL13RÎ±2 expression identifies tissueâ€resident ILâ€22â€producing PLZF⁺ innate TÂcells in the human liver. European Journal of Immunology, 2018, 48, 1329-1335.	1.6	13
50	A-104 Immune Targeting of the Latent Reservoir. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 33-33.	0.9	0
51	The CD4^{â^'}CD8^{â^'}MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8⁺MAIT cell pool. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11513-E11522.	3.3	147
52	Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. Journal of Clinical Investigation, 2018, 128, 876-889.	3.9	157
53	Evidence that CD32a does notÂmark the HIV-1 latent reservoir. Nature, 2018, 561, E20-E28.	13.7	43
54	Dicer-2 Regulates Resistance and Maintains Homeostasis against Zika Virus Infection in Drosophila. Journal of Immunology, 2018, 201, 3058-3072.	0.4	41

#	Article	IF	Citations
55	HLA-C downregulation by HIV-1 adapts to host HLA genotype. PLoS Pathogens, 2018, 14, e1007257.	2.1	30
56	Human interleukin-34-derived macrophages have increased resistance to HIV-1 infection. Cytokine, 2018, 111, 272-277.	1.4	13
57	The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles. Blood Advances, 2018, 2, 76-84.	2.5	78
58	Allatostatin C modulates nociception and immunity in Drosophila. Scientific Reports, 2018, 8, 7501.	1.6	40
59	Influence of Biological Sex, Age, and HIV Status in anIn VitroPrimary Cell Model of HIV Latency Using a CXCR4 Tropic Virus. AIDS Research and Human Retroviruses, 2018, 34, 769-777.	0.5	21
60	Latent Mycobacterium tuberculosis Infection Is Associated With a Higher Frequency of Mucosal-Associated Invariant T and Invariant Natural Killer T Cells. Frontiers in Immunology, 2018, 9, 1394.	2.2	33
61	Comprehensive Antiretroviral Restriction Factor Profiling Reveals the Evolutionary Imprint of the ex Vivo and in Vivo IFN-Î² Response in HTLV-1-Associated Neuroinflammation. Frontiers in Microbiology, 2018, 9, 985.	1.5	12
62	TGF-Î² Sustains Tumor Progression through Biochemical and Mechanical Signal Transduction. Cancers, 2018, 10, 199.	1.7	32
63	Biomimetic Placenta-Fetus Model Demonstrating Maternalâ€“Fetal Transmission and Fetal Neural Toxicity of Zika Virus. Annals of Biomedical Engineering, 2018, 46, 1963-1974.	1.3	28
64	MAIT cells are activated in acute Dengue virus infection and after in vitro Zika virus infection. PLoS Neglected Tropical Diseases, 2018, 12, e0006154.	1.3	38
65	Restriction of HIV-1 Infection in Sickle Cell Disease and Trait. Blood, 2018, 132, 2337-2337.	0.6	0
66	HTLV-1 Tax activates HIV-1 transcription in latency models. Virology, 2017, 504, 45-51.	1.1	14
67	Immune activation in amniotic fluid from Zika virusâ€“associated microcephaly. Annals of Neurology, 2017, 81, 152-156.	2.8	53
68	Psoriasis risk SNPs and their association with HIV-1 control. Human Immunology, 2017, 78, 179-184.	1.2	10
69	A Fashi Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation. Frontiers in Immunology, 2017, 8, 97.	2.2	14
70	Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers. Retrovirology, 2017, 14, 41.	0.9	22
71	IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis. JCI Insight, 2017, 2, e85811.	2.3	10
72	MAIT cells are reduced in frequency and functionally impaired in human T lymphotropic virus type 1 infection: Potential clinical implications. PLoS ONE, 2017, 12, e0175345.	1.1	33

#	Article	IF	Citations
73	Enriched environment and stress exposure influence splenic B lymphocyte composition. PLoS ONE, 2017, 12, e0180771.	1.1	26
74	T-cell Responses in Individuals Infected with Zika Virus and in Those Vaccinated Against Dengue Virus. Pathogens and Immunity, 2017, 2, 274.	1.4	18
75	Loss of Circulating Mucosal-Associated Invariant T Cells in Common Variable Immunodeficiency Is Associated with Immune Activation and Loss of Eomes and PLZF. ImmunoHorizons, 2017, 1, 142-155.	0.8	8
76	p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. PLoS ONE, 2016, 11, e0166759.	1.1	10
77	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 184-188.	0.9	1
78	Innate Invariant NKT Cell Recognition of HIV-1â€“Infected Dendritic Cells Is an Early Detection Mechanism Targeted by Viral Immune Evasion. Journal of Immunology, 2016, 197, 1843-1851.	0.4	20
79	Effects of a mindfulnessâ€based weight loss intervention in adults with obesity: A randomized clinical trial. Obesity, 2016, 24, 794-804.	1.5	113
80	Inversion of the VÎ´1 to VÎ´2 Î³Î´ T cell ratio in CVID is not restored by IVIg and is associated with immune activation and exhaustion. Medicine (United States), 2016, 95, e4304.	0.4	10
81	T-cell therapies for HIV: Preclinical successes and current clinical strategies. Cytotherapy, 2016, 18, 931-942.	0.3	36
82	Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+T-Cell Activation. Journal of Infectious Diseases, 2016, 213, 569-573.	1.9	11
83	Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8379-8384.	3.3	14
84	Modulating APOBEC expression enhances DNA vaccine immunogenicity. Immunology and Cell Biology, 2015, 93, 868-876.	1.0	6
85	Test, Treat, and Cure. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, e9-e10.	0.9	0
86	Human T-Lymphotropic Virus 1, Breastfeeding, and Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2015, 31, 271-271.	0.5	4
87	Newly Exerted T Cell Pressures on Mutated Epitopes following Transmission Help Maintain Consensus HIV-1 Sequences. PLoS ONE, 2015, 10, e0120787.	1.1	3
88	Environmental Enrichment Alters Splenic Immune Cell Composition and Enhances Secondary Influenza Vaccine Responses in Mice. Molecular Medicine, 2014, 20, 179-190.	1.9	25
89	Cutting Edge: An Antibody Recognizing Ancestral Endogenous Virus Glycoproteins Mediates Antibody-Dependent Cellular Cytotoxicity on HIV-1â€“Infected Cells. Journal of Immunology, 2014, 193, 1544-1548.	0.4	21
90	Dynamic Regulation of Host Restriction Factor Expression over the Course of HIV-1 Infection In Vivo. Journal of Virology, 2014, 88, 11624-11629.	1.5	15

#	Article	IF	Citations
91	<scp>HIV</scp>â€1 drug resistance prevalence, drug susceptibility and variant characterization in the <scp>J</scp>acobi <scp>M</scp>edical <scp>C</scp>enter paediatric cohort, <scp>B</scp>ronx, <scp>NY</scp>, <scp>USA</scp>. HIV Medicine, 2014, 15, 135-143.	1.0	10
92	Diminished humoral responses against and reduced gene expression levels of human endogenous retrovirus-K (HERV-K) in psoriasis. Journal of Translational Medicine, 2014, 12, 256.	1.8	16
93	Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. Retrovirology, 2014, 11, 10.	0.9	43
94	Acquisition of innate-like microbial reactivity in mucosal tissues during human fetal MAIT-cell development. Nature Communications, 2014, 5, 3143.	5.8	201
95	Invariant natural killer T cells developing in the human fetus accumulate and mature in the small intestine. Mucosal Immunology, 2014, 7, 1233-1243.	2.7	40
96	The CD8 ⁺ Memory Stem T Cell (T _{SCM}) Subset Is Associated with Improved Prognosis in Chronic HIV-1 Infection. Journal of Virology, 2014, 88, 13836-13844.	1.5	53
97	Composition and Function of T Cell Subpopulations Are Slow to Change Despite Effective Antiretroviral Treatment of HIV Disease. PLoS ONE, 2014, 9, e85613.	1.1	41
98	Vaccination against Endogenous Retrotransposable Element Consensus Sequences Does Not Protect Rhesus Macaques from SIVsmE660 Infection and Replication. PLoS ONE, 2014, 9, e92012.	1.1	8
99	Human Endogenous Retrovirus K(HML-2) Gag and Env specific T-cell responses are not detected in HTLV-I-infected subjects using standard peptide screening methods. Journal of Negative Results in BioMedicine, 2013, 12, 3.	1.4	12
100	Effects of Cellular Activation on Anti-HIV-1 Restriction Factor Expression Profile in Primary Cells. Journal of Virology, 2013, 87, 11924-11929.	1.5	34
101	CD56negCD16+NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology, 2013, 10, 158.	0.9	104
102	Invariant natural killer <scp>T</scp> (i<scp>NKT</scp>) cell exhaustion in sarcoidosis. European Journal of Immunology, 2013, 43, 2194-2205.	1.6	37
103	Skewed distribution of natural killer cells in psoriasis skin lesions. Experimental Dermatology, 2013, 22, 64-66.	1.4	38
104	Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology, 2013, 10, 106.	0.9	79
105	T Cells Target APOBEC3 Proteins in Human Immunodeficiency Virus Type 1-Infected Humans and Simian Immunodeficiency Virus-Infected Indian Rhesus Macaques. Journal of Virology, 2013, 87, 6073-6080.	1.5	6
106	Expansion in CD39+ CD4+ Immunoregulatory T Cells and Rarity of Th17 Cells in HTLV-1 Infected Patients Is Associated with Neurological Complications. PLoS Neglected Tropical Diseases, 2013, 7, e2028.	1.3	27
107	Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals. Journal of Leukocyte Biology, 2013, 94, 1051-1059.	1.5	15
108	Targeting of Conserved Gag-Epitopes in Early HIV Infection Is Associated with Lower Plasma Viral Load and Slower CD4⁺T Cell Depletion. AIDS Research and Human Retroviruses, 2013, 29, 602-612.	0.5	11

#	Article	IF	Citations
109	LINE-1 Retrotransposable Element DNA Accumulates in HIV-1-Infected Cells. Journal of Virology, 2013, 87, 13307-13320.	1.5	54
110	Differentiation and functional regulation of human fetal NK cells. Journal of Clinical Investigation, 2013, 123, 3889-3901.	3.9	108
111	Variability of HIV-1 Genomes among Children and Adolescents from SÃ£o Paulo, Brazil. PLoS ONE, 2013, 8, e62552.	1.1	18
112	CD57 Expression and Cytokine Production by T Cells in Lesional and Unaffected Skin from Patients with Psoriasis. PLoS ONE, 2013, 8, e52144.	1.1	10
113	Psoriasis Patients Are Enriched for Genetic Variants That Protect against HIV-1 Disease. PLoS Genetics, 2012, 8, e1002514.	1.5	66
114	Protective Effect of Human Endogenous Retrovirus K dUTPase Variants on Psoriasis Susceptibility. Journal of Investigative Dermatology, 2012, 132, 1833-1840.	0.3	22
115	Decay Kinetics of HIV-1 Specific T Cell Responses in Vertically HIV-1 Exposed Seronegative Infants. Frontiers in Immunology, 2012, 2, 94.	2.2	7
116	Human Endogenous Retrovirus K(HML-2) Gag- and Env-Specific T-Cell Responses Are Infrequently Detected in HIV-1-Infected Subjects Using Standard Peptide Matrix-Based Screening. Vaccine Journal, 2012, 19, 288-292.	3.2	13
117	HIV-1 Vpu Interference with Innate Cell-mediated Immune Mechanisms. Current HIV Research, 2012, 10, 327-333.	0.2	20
118	Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood, 2012, 119, 745-755.	0.6	38
119	Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood, 2012, 119, 3734-3743.	0.6	406
120	Influence of HAART on Alternative Reading Frame Immune Responses over the Course of HIV-1 Infection. PLoS ONE, 2012, 7, e39311.	1.1	17
121	Human Endogenous Retrovirus Expression Is Inversely Associated with Chronic Immune Activation in HIV-1 Infection. PLoS ONE, 2012, 7, e41021.	1.1	26
122	Differential Expression of CD96 Surface Molecule Represents CD8+ T Cells with Dissimilar Effector Function during HIV-1 Infection. PLoS ONE, 2012, 7, e51696.	1.1	15
123	The Calm Mouse: An Animal Model of Stress Reduction. Molecular Medicine, 2012, 18, 606-617.	1.9	40
124	Vaccination with Cancer- and HIV Infection-Associated Endogenous Retrotransposable Elements Is Safe and Immunogenic. Journal of Immunology, 2012, 189, 1467-1479.	0.4	46
125	Lower numbers of natural killer T cells in HIVâ€1 and Mycobacterium leprae coâ€infected patients. Immunology, 2012, 136, 96-102.	2.0	4
126	HERV-Kâ€“specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. Journal of Clinical Investigation, 2012, 122, 4473-4489.	3.9	81

#	Article	IF	Citations
127	Association of Differentiation State of CD4+ T Cells and Disease Progression in HIV-1 Perinatally Infected Children. PLoS ONE, 2012, 7, e29154.	1.1	4
128	Age-Related Expansion of Tim-3 Expressing T Cells in Vertically HIV-1 Infected Children. PLoS ONE, 2012, 7, e45733.	1.1	17
129	Associations between Antibodies to a Panel of Plasmodium falciparum Specific Antigens and Response to Sub-Optimal Antimalarial Therapy in Kampala, Uganda. PLoS ONE, 2012, 7, e52571.	1.1	8
130	Immunodominance of HIV-1 Specific CD8+ T-Cell Responses Is Related to Disease Progression Rate in Vertically Infected Adolescents. PLoS ONE, 2011, 6, e21135.	1.1	6
131	NK Cells and CD1dâ€restricted NKT Cells Respond in Different Ways with Divergent Kinetics to ILâ€2 Treatment in Primary HIVâ€1 Infection. Scandinavian Journal of Immunology, 2011, 73, 141-146.	1.3	10
132	Strong Human Endogenous Retrovirus-Specific T Cell Responses Are Associated with Control of HIV-1 in Chronic Infection. Journal of Virology, 2011, 85, 6977-6985.	1.5	50
133	Identification of Human Endogenous Retrovirus-Specific T Cell Responses in Vertically HIV-1-Infected Subjects. Journal of Virology, 2011, 85, 11526-11531.	1.5	29
134	Expansion of a unique CD57⁺NKG2C^{hi}natural killer cell subset during acute human cytomegalovirus infection. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14725-14732.	3.3	725
135	HTLV-1 Tax Specific CD8+ T Cells Express Low Levels of Tim-3 in HTLV-1 Infection: Implications for Progression to Neurological Complications. PLoS Neglected Tropical Diseases, 2011, 5, e1030.	1.3	29
136	Human Endogenous Retrovirus K106 (HERV-K106) Was Infectious after the Emergence of Anatomically Modern Humans. PLoS ONE, 2011, 6, e20234.	1.1	46
137	A novel human CD4⁺ Tâ€cell inducer subset with potent immunostimulatory properties. European Journal of Immunology, 2010, 40, 134-141.	1.6	14
138	Immune Escape Mutations Detected Within HIV-1 Epitopes Associated With Viral Control During Treatment Interruption. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 36-46.	0.9	10
139	CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood, 2010, 116, 3865-3874.	0.6	636
140	IL-2 Immunotherapy to Recently HIV-1 Infected Adults Maintains the Numbers of IL-17 Expressing CD4+ T (TH17) Cells in the Periphery. Journal of Clinical Immunology, 2010, 30, 681-692.	2.0	10
141	Increased number and function of natural killer cells in human immunodeficiency virus 1â€positive subjects coâ€infected with herpes simplex virus 2. Immunology, 2010, 129, 186-196.	2.0	15
142	Skewed Distribution of Circulating Activated Natural Killer T (NKT) Cells in Patients with Common Variable Immunodeficiency Disorders (CVID). PLoS ONE, 2010, 5, e12652.	1.1	28
143	A Comprehensive Ex Vivo Functional Analysis of Human NKT Cells Reveals Production of MIP1-Î± and MIP1-Î², a Lack of IL-17, and a Th1-Bias in Males. PLoS ONE, 2010, 5, e15412.	1.1	45
144	T Cell Immunity in Acute HIVâ€1 Infection. Journal of Infectious Diseases, 2010, 202, S302-S308.	1.9	80

#	Article	IF	Citations
145	Rapid Progressing Allele HLA-B35 Px Restricted Anti-HIV-1 CD8+ T Cells Recognize Vestigial CTL Epitopes. PLoS ONE, 2010, 5, e10249.	1.1	16
146	HIV-1-Specific T Cell-Dependent Natural Killer (NK) Cell Activation: Major Contribution by NK Cells to Interferon-Î³ Production in Response to HIV-1 Antigens. AIDS Research and Human Retroviruses, 2009, 25, 603-605.	0.5	8
147	Cross-Sectional Dating of Novel Haplotypes of HERV-K 113 and HERV-K 115 Indicate These Proviruses Originated in Africa before Homo sapiens. Molecular Biology and Evolution, 2009, 26, 2617-2626.	3.5	34
148	Transcriptional Errors in Human Immunodeficiency Virus Type 1 Generate Targets for T-Cell Responses. Vaccine Journal, 2009, 16, 1369-1371.	3.2	14
149	Interleukinâ€10â€secreting T cells define a suppressive subset within the HIVâ€1â€specific Tâ€cell population. European Journal of Immunology, 2009, 39, 1280-1287.	1.6	18
150	Lower numbers of circulating natural killer T (NK T) cells in individuals with human T lymphotropic virus type 1 (HTLV-1) associated neurological disease. Clinical and Experimental Immunology, 2009, 158, 294-299.	1.1	19
151	P16-30. Induction of Tim-3 expression by the common gamma-chain cytokines IL-2, IL-7, IL-15 and IL-21. Retrovirology, 2009, 6, .	0.9	0
152	P16-10. IL-2 therapy mediates expansion of Treg cells, maintains IL-17 expressing CD4+ T-cells and selectively suppresses HIV specific T-cell responses. Retrovirology, 2009, 6, .	0.9	0
153	HIV-1 infection induces retrotransposition of LINE-1 elements. Retrovirology, 2009, 6, .	0.9	2
154	Paleovirology of human endogenous retroviruses. Retrovirology, 2009, 6, .	0.9	0
155	Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infectious Diseases, The, 2009, 9, 74.	4.6	6
156	Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. Aids, 2009, 23, 1965-1970.	1.0	36
157	Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood, 2009, 114, 4823-4831.	0.6	91
158	Tregs control the development of symptomatic West Nile virus infection in humans and mice. Journal of Clinical Investigation, 2009, 119, 3266-77.	3.9	181
159	A Decreased Frequency of Regulatory T Cells in Patients with Common Variable Immunodeficiency. PLoS ONE, 2009, 4, e6269.	1.1	54
160	Nineâ€color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 400-410.	1.1	65
161	Nineâ€color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part II: Panel performance across different instrument platforms. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 411-420.	1.1	25
162	The frequency of CD127low expressing CD4+CD25high T regulatory cells is inversely correlated with human T lymphotrophic virus type-1 (HTLV-1) proviral load in HTLV-1-infection and HTLV-1-associated myelopathy/tropical spastic paraparesis. BMC Immunology, 2008, 9, 41.	0.9	21

#	Article	IF	Citations
163	Maternal Alloantigens Promote the Development of Tolerogenic Fetal Regulatory T Cells in Utero. Science, 2008, 322, 1562-1565.	6.0	749
164	Potentially Exposed but Uninfected Individuals Produce Cytotoxic and Polyfunctional Human Immunodeficiency Virus Type 1-Specific CD8⁺T-Cell Responses Which Can Be Defined to the Epitope Level. Vaccine Journal, 2008, 15, 1745-1748.	3.2	30
165	Immune Reconstitution of CD56dimNK Cells in Individuals with Primary HIVâ€1 Infection Treated with Interleukinâ€2. Journal of Infectious Diseases, 2008, 197, 117-125.	1.9	27
166	FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection. Journal of Leukocyte Biology, 2008, 83, 254-262.	1.5	86
167	Single-Cell, Phosphoepitope-Specific Analysis Demonstrates Cell Type- and Pathway-Specific Dysregulation of Jak/STAT and MAPK Signaling Associated with In Vivo Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2008, 82, 3702-3712.	1.5	24
168	Broadly Immunogenic HLA Class I Supertype-Restricted Elite CTL Epitopes Recognized in a Diverse Population Infected with Different HIV-1 Subtypes. Journal of Immunology, 2008, 180, 5092-5100.	0.4	51
169	Conferral of Enhanced Natural Killer Cell Function by KIR3DS1 in Early Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2008, 82, 4785-4792.	1.5	98
170	Immunity to HIV-1 Is Influenced by Continued Natural Exposure to Exogenous Virus. PLoS Pathogens, 2008, 4, e1000185.	2.1	14
171	Elevated Frequency of Gamma Interferon-Producing NK Cells in Healthy Adults Vaccinated against Influenza Virus. Vaccine Journal, 2008, 15, 120-130.	3.2	62
172	Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. Journal of Experimental Medicine, 2008, 205, 2763-2779.	4.2	681
173	Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection. Aids, 2008, 22, 990-992.	1.0	66
174	Nucleoside Analogue Reverse Transcriptase Inhibitors Differentially Inhibit Human LINE-1 Retrotransposition. PLoS ONE, 2008, 3, e1547.	1.1	78
175	Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. Journal of Cell Biology, 2008, 183, i9-i9.	2.3	0
176	Antiretroviral Drug Therapy Alters the Profile of Human Immunodeficiency Virus Type 1-Specific T-Cell Responses and Shifts the Immunodominant Cytotoxic T-Lymphocyte Response from Gag to Pol. Journal of Virology, 2007, 81, 11543-11548.	1.5	15
177	Cutting Edge: KIR3DS1, a Gene Implicated in Resistance to Progression to AIDS, Encodes a DAP12-Associated Receptor Expressed on NK Cells That Triggers NK Cell Activation. Journal of Immunology, 2007, 178, 647-651.	0.4	129
178	Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8 + T EMRA Cells in Early Infection Are Linked to Control of HIV-1 Viremia and Predict the Subsequent Viral Load Set Point. Journal of Virology, 2007, 81, 5759-5765.	1.5	73
179	Natural Killer Cells in Perinatally HIV-1-Infected Children Exhibit Less Degranulation Compared to HIV-1-Exposed Uninfected Children and Their Expression of KIR2DL3, NKG2C, and NKp46 Correlates with Disease Severity. Journal of Immunology, 2007, 179, 3362-3370.	0.4	65
180	T Cell Responses to Human Endogenous Retroviruses in HIV-1 Infection. PLoS Pathogens, 2007, 3, e165.	2.1	114

#	Article	IF	Citations
181	Individuals with Pulmonary Tuberculosis Have Lower Levels of Circulating CD1dâ€Restricted NKT Cells. Journal of Infectious Diseases, 2007, 195, 1361-1364.	1.9	68
182	Rational Peptide Selection To Detect Human Immunodeficiency Virus Type 1-Specific T-Cell Responses under Resource-Limited Conditions. Vaccine Journal, 2007, 14, 785-788.	3.2	1
183	Treatment interruption in chronic HIV-1 infection: does it deliver?. Current Opinion in HIV and AIDS, 2007, 2, 26-30.	1.5	2
184	HIV-1/HSV-2 Co-Infected Adults in Early HIV-1 Infection Have Elevated CD4+ T Cell Counts. PLoS ONE, 2007, 2, e1080.	1.1	24
185	Sequential Broadening of CTL Responses in Early HIV-1 Infection Is Associated with Viral Escape. PLoS ONE, 2007, 2, e225.	1.1	68
186	Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques. Retrovirology, 2006, 3, 97.	0.9	14
187	Regulation of T Cell Responses in the Developing Human Fetus. Journal of Immunology, 2006, 176, 5741-5748.	0.4	219
188	Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2. Blood, 2006, 107, 3081-3083.	0.6	52
189	IL-2 production correlates with effector cell differentiation in HIV-specific CD8+ T cells. AIDS Research and Therapy, 2006, 3, 18.	0.7	22
190	HIV-1-Specific CD4+ T Cell Responses in Chronically HIV-1 Infected Blippers on Antiretroviral Therapy in Relation to Viral Replication Following Treatment Interruption. Journal of Clinical Immunology, 2006, 26, 40-54.	2.0	19
191	CD8 T cell effector maturation in HIV-1-infected children. Virology, 2006, 347, 117-126.	1.1	11
192	A Plea for Justice for Jailed Medical Workers. Science, 2006, 314, 924-925.	6.0	3
193	Seroreversion in Subjects Receiving Antiretroviral Therapy during Acute/Early HIV Infection. Clinical Infectious Diseases, 2006, 42, 700-708.	2.9	87
194	Detection of T Lymphocytes Specific for Human Endogenous Retrovirus K (HERV-K) in Patients with Seminoma. AIDS Research and Human Retroviruses, 2006, 22, 52-56.	0.5	53
195	Strong HIV-1-Specific T Cell Responses in HIV-1-Exposed Uninfected Infants and Neonates Revealed after Regulatory T Cell Removal. PLoS ONE, 2006, 1, e102.	1.1	129
196	Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. Aids, 2005, 19, 1575-1585.	1.0	13
197	CD4+CD25+ regulatory T cells in HIV infection. Microbes and Infection, 2005, 7, 1063-1065.	1.0	38
198	Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment. Journal of Virology, 2005, 79, 14169-14178.	1.5	207

#	Article	IF	Citations
199	Higher Frequency of HIVâ€1â€“Specific T Cell Immune Responses in African American Children Vertically Infected with HIVâ€1. Journal of Infectious Diseases, 2005, 192, 1772-1780.	1.9	12
200	Evaluation of CD8+ T-cell and antibody responses following transient increased viraemia in rhesus macaques infected with live, attenuated simian immunodeficiency virus. Journal of General Virology, 2005, 86, 3375-3384.	1.3	12
201	Multidrug-resistant, dual-tropic HIV-1 and rapid progression. Lancet, The, 2005, 365, 1924-1925.	6.3	4
202	Title is missing!. Retrovirology, 2005, 2, S107.	0.9	0
203	Abundant Expression of Granzyme A, but Not Perforin, in Granules of CD8+ T Cells in GALT: Implications for Immune Control of HIV-1 Infection. Journal of Immunology, 2004, 173, 641-648.	0.4	58
204	Increased Adhesion Molecule and Chemokine Receptor Expression on CD8+T Cells Trafficking to Cerebrospinal Fluid in HIVâ€1 Infection. Journal of Infectious Diseases, 2004, 189, 2202-2212.	1.9	73
205	R5 Human Immunodeficiency Virus Type 1 (HIV-1) Replicates More Efficiently in Primary CD4 + T-Cell Cultures Than X4 HIV-1. Journal of Virology, 2004, 78, 9164-9173.	1.5	32
206	Highly Effective Control of an AIDS Virus Challenge in Macaques by Using Vesicular Stomatitis Virus and Modified Vaccinia Virus Ankara Vaccine Vectors in a Single-Boost Protocol. Journal of Virology, 2004, 78, 3930-3940.	1.5	96
207	Development of innate CD4+ Â-chain variable gene segment 24 (VÂ24) natural killer T cells in the early human fetal thymus is regulated by IL-7. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7058-7063.	3.3	68
208	Human CD4 + CD25 + Regulatory T Cells Control T-Cell Responses to Human Immunodeficiency Virus and Cytomegalovirus Antigens. Journal of Virology, 2004, 78, 2454-2459.	1.5	411
209	Limited Magnitude and Breadth in the HLA-A2-Restricted CD8 T-Cell Response to Nef in Children with Vertically Acquired HIV-1 Infection. Scandinavian Journal of Immunology, 2004, 59, 109-114.	1.3	8
210	Poorly soluble peptides can mimic authentic ELISPOT responses. Journal of Immunological Methods, 2004, 285, 89-92.	0.6	13
211	ELISPOT cell rescue. Journal of Immunological Methods, 2004, 288, 135-147.	0.6	13
212	Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. Aids, 2004, 18, 981-989.	1.0	101
213	Relevance of HIV-1-Specific CD4+ Helper T-Cell Responses During Structured Treatment Interruptions in Patients With CD4+ T-Cell Nadir Above 400/mm3. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 791-799.	0.9	34
214	Expansion of CD7low and CD7negative CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment. Blood, 2004, 104, 3672-3678.	0.6	32
215	Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. Journal of Immunological Methods, 2003, 283, 141-153.	0.6	200
216	Optimization of methods to assess human mucosal T-cell responses to HIV infection. Journal of Immunological Methods, 2003, 279, 17-31.	0.6	96

#	Article	IF	Citations
217	Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate VÎ±24 NKT cell compartment. European Journal of Immunology, 2003, 33, 588-596.	1.6	83
218	Trafficking of Human Immunodeficiency Virus Type 1-Specific CD8 + T Cells to Gut-Associated Lymphoid Tissue during Chronic Infection. Journal of Virology, 2003, 77, 5621-5631.	1.5	71
219	Presence of Human Immunodeficiency Virusâ€"1â€"Specific CD4 and CD8 Cellular Immune Responses in Children with Full or Partial Virus Suppression. Journal of Infectious Diseases, 2003, 188, 873-882.	1.9	18
220	HIV-Specific CD8+ T Cell Function in Children with Vertically Acquired HIV-1 Infection Is Critically Influenced by Age and the State of the CD4+ T Cell Compartment. Journal of Immunology, 2003, 170, 4403-4410.	0.4	61
221	CD7 Is a Differentiation Marker That Identifies Multiple CD8 T Cell Effector Subsets. Journal of Immunology, 2003, 170, 2349-2355.	0.4	66
222	Changes in CD4+ T-Cell Differentiation Phenotype During Structured Treatment Interruption in Patients With Chronic HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 475-481.	0.9	21
223	New observations on CD8 cell responses. Aids, 2003, 17, S61-S65.	1.0	2
224	Dual Pressure from Antiretroviral Therapy and Cell-Mediated Immune Response on the Human Immunodeficiency Virus Type 1 Protease Gene. Journal of Virology, 2003, 77, 6743-6752.	1.5	46
225	Boosting of SIV-Specific T Cell Responses in Rhesus Macaques That Resist Repeated Intravaginal Challenge with SIVmac251. AIDS Research and Human Retroviruses, 2002, 18, 1081-1088.	0.5	7
226	Dendritic Cell Amplification of HIV Type 1-Specific CD8+T Cell Responses in Exposed, Seronegative Heterosexual Women. AIDS Research and Human Retroviruses, 2002, 18, 805-815.	0.5	20
227	Inhibition of Antigen-Specific T Cell Proliferation and Cytokine Production by Protein Kinase A Type I. Journal of Immunology, 2002, 169, 802-808.	0.4	93
228	Generation of CD3+CD8low Thymocytes in the HIV Type 1-Infected Thymus. Journal of Immunology, 2002, 169, 2788-2796.	0.4	40
229	Selective Loss of Innate CD4+ VÎ±24 Natural Killer T Cells in Human Immunodeficiency Virus Infection. Journal of Virology, 2002, 76, 7528-7534.	1.5	152
230	Correlates of Nontransmission in US Women at High Risk of Human Immunodeficiency Virus Type 1 Infection through Sexual Exposure. Journal of Infectious Diseases, 2002, 185, 428-438.	1.9	66
231	Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells. Aids, 2002, 16, 171-180.	1.0	39
232	Residual Viral Replication during Antiretroviral Therapy Boosts Human Immunodeficiency Virus Type 1-Specific CD8 + T-Cell Responses in Subjects Treated Early after Infection. Journal of Virology, 2002, 76, 411-415.	1.5	25
233	T lymphocyte responses against human parvovirus B19: small virus, big response. Pathologie Et Biologie, 2002, 50, 317-325.	2.2	12
234	Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15â€"the Amplispot assay. Journal of Immunological Methods, 2002, 270, 99-108.	0.6	66

#	Article	IF	Citations
235	Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. Aids, 2002, 16, 2342-2344.	1.0	47
236	An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants. Cell, 2001, 106, 539-549.	13.5	432
237	Inhibition of Human Immunodeficiency Virus Type 1 gp120 Presentation to CD4 T Cells by Antibodies Specific for the CD4 Binding Domain of gp120. Journal of Virology, 2001, 75, 10950-10957.	1.5	26
238	The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. Aids, 2001, 15, F29-F40.	1.0	160
239	Direct Measurement of CD4+ and CD8+ T-Cell Responses to CMV in HIV-1-Infected Subjects. Virology, 2001, 279, 459-470.	1.1	92
240	A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. Journal of Immunological Methods, 2001, 249, 99-110.	0.6	150
241	Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13288-13293.	3.3	150
242	Functional Heterogeneity of Cytokines and Cytolytic Effector Molecules in Human CD8+ T Lymphocytes. Journal of Immunology, 2001, 167, 181-187.	0.4	145
243	Direct Ex Vivo Measurement of CD8+T-Lymphocyte Responses to Human Parvovirus B19. Journal of Virology, 2001, 75, 540-543.	1.5	42
244	A simple and rapid magnetic bead separation technique for the isolation of tetramer-positive virus-specific CD8 T cells. Aids, 2001, 15, 810-812.	1.0	12
245	Requirement of Mature Dendritic Cells for Efficient Activation of Influenza A-Specific Memory CD8+ T Cells. Journal of Immunology, 2000, 165, 1182-1190.	0.4	123
246	Quantification of HIV-1-specific T-cell responses at the mucosal cervicovaginal surface. Aids, 2000, 14, 1911-1915.	1.0	43
247	Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. Aids, 2000, 14, 2313-2322.	1.0	117
248	Characterization of HIV-1-Specific Cytotoxic T Lymphocytes Expressing the Mucosal Lymphocyte Integrin CD103 in Rectal and Duodenal Lymphoid Tissue of HIV-1-Infected Subjects. Virology, 2000, 270, 317-327.	1.1	33
249	Direct Measurement of CD8+ T Cell Responses in Macaques Infected with Simian Immunodeficiency Virus. Virology, 2000, 272, 347-356.	1.1	33
250	Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes and Protection Against Challenge in Rhesus Macaques Immunized with a Live Attenuated Simian Immunodeficiency Virus Vaccine. Virology, 2000, 266, 203-210.	1.1	41
251	An Antigenic Threshold for Maintaining Human Immunodeficiency Virus Type 1-specific Cytotoxic T Lymphocytes. Molecular Medicine, 2000, 6, 803-809.	1.9	33
252	Enhancement of Human Immunodeficiency Virus Type 1â€“Specific CD4 and CD8 T Cell Responses in Chronically Infected Persons after Temporary Treatment Interruption. Journal of Infectious Diseases, 2000, 182, 766-775.	1.9	108

#	Article	IF	Citations
253	Identification of Subdominant Cytotoxic T Lymphocyte Epitopes Encoded by Autologous HIV Type 1 Sequences, Using Dendritic Cell Stimulation and Computer-Driven Algorithm. AIDS Research and Human Retroviruses, 2000, 16, 67-76.	0.5	31
254	High Frequency of Cytomegalovirusâ€Specific Cytotoxic Tâ€Effector Cells in HLAâ€A*0201â€“Positive Subjects during Multiple Viral Coinfections. Journal of Infectious Diseases, 2000, 181, 165-175.	1.9	65
255	The Impact of Early Initiation of Highly Active Antiretroviral Therapy on the Human Immunodeficiency Virus Type 1â€“Specific CD8 T Cell Response in Children. Journal of Infectious Diseases, 2000, 182, 88-95.	1.9	37
256	Strong Human Immunodeficiency Virus (HIV)â€“Specific CD4+T Cell Responses in a Cohort of Chronically Infected Patients Are Associated with Interruptions in Antiâ€HIV Chemotherapy. Journal of Infectious Diseases, 2000, 181, 1264-1272.	1.9	75
257	Human Immunodeficiency Virus Type 1- and Cytomegalovirus-Specific Cytotoxic T Lymphocytes Can Persist at High Frequency for Prolonged Periods in the Absence of Circulating Peripheral CD4+ T Cells. Journal of Virology, 2000, 74, 1018-1022.	1.5	89
258	HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function. Journal of Experimental Medicine, 2000, 192, 63-76.	4.2	820
259	The Relationship between T Cell Proliferative Responses and Plasma Viremia during Treatment of Human Immunodeficiency Virus Type 1 Infection with Combination Antiretroviral Therapy. Journal of Infectious Diseases, 2000, 181, 1249-1263.	1.9	45
260	Isolation of Cytomegalovirus-Specific Cytotoxic T-Lymphocytes from Gut-Associated Lymphoid Tissue (GALT) of HIV Type 1-Infected Subjects. AIDS Research and Human Retroviruses, 2000, 16, 1157-1162.	0.5	8
261	Why do cytotoxic T lymphocytes fail to eliminate hepatitis C virus? Lessons from studies using major histocompatibility complex class I peptide tetramers. Philosophical Transactions of the Royal Society B: Biological Sciences, 2000, 355, 1085-1092.	1.8	28
262	Evaluation of a Lipopeptide Immunogen as a Therapeutic in HIV Type 1-Seropositive Individuals. AIDS Research and Human Retroviruses, 2000, 16, 337-343.	0.5	33
263	Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry. Aids, 2000, 14, 2625-2627.	1.0	35
264	The Effect of Commencing Combination Antiretroviral Therapy Soon after Human Immunodeficiency Virus Type 1 Infection on Viral Replication and Antiviral Immune Responses. Journal of Infectious Diseases, 1999, 179, 527-537.	1.9	174
265	Molecular tracking of an Human Immunodeficiency Virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy. Immunology Letters, 1999, 66, 219-228.	1.1	15
266	Comparison of restimulation methods to elicit SIV specific cytotoxic T-lymphocytes (CTL) in vitro: Staphylococcal Enterotoxin B (SEB) provides a novel method for the quantification of SIV specific CTL precursors. Immunology Letters, 1999, 66, 135-140.	1.1	5
267	A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. Aids, 1999, 13, 767-777.	1.0	206
268	Strong Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Activity in Sydney Blood Bank Cohort Patients Infected withnef-Defective HIV Type 1. Journal of Virology, 1999, 73, 436-443.	1.5	103
269	Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. Journal of Clinical Investigation, 1999, 104, 173-180.	3.9	409
270	HIV-1â€“specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. Journal of Clinical Investigation, 1999, 104, R13-R18.	3.9	215

#	Article	IF	Citations
271	Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA. Science, 1998, 279, 2103-2106.	6.0	1,340
272	Longitudinal and Crossâ€Sectional Analysis of Cytotoxic T Lymphocyte Responses and Their Relationship to Vertical Human Immunodeficiency Virus Transmission. Journal of Infectious Diseases, 1998, 178, 1317-1326.	1.9	29
273	CTL induction using synthetic peptides delivered in emulsionsâ€" critical role of the formulation procedure. Vaccine, 1997, 15, 1773-1778.	1.7	10
274	Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine, 1996, 14, 412-418.	1.7	29
275	Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine, 1996, 14, 1523-1530.	1.7	121
276	Cytotoxic T cell induction with ratchet peptide libraries. Vaccine, 1996, 14, 1664-1670.	1.7	1
277	Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. European Journal of Immunology, 1996, 26, 1951-1959.	1.6	89
278	A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides. European Journal of Immunology, 1993, 23, 447-453.	1.6	105
279	Cytotoxic T lymphocyte epitopes shared between HIVâ€1, HIVâ€2, and SIV. Journal of Medical Primatology, 1993, 22, 119-123.	0.3	12
280	Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature, 1991, 354, 453-459.	13.7	1,060
281	An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. Aids, 1990, 4, 841-846.	1.0	39
282	Structural homologies between two HLA B27-restricted peptides suggest residues important for interaction with HLA B27. International Immunology, 1990, 2, 311-316.	1.8	105
283	T-cell strategies in AIDS vaccines. Aids, 1989, 3, S101-110.	1.0	27
284	HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature, 1988, 336, 484-487.	13.7	471
285	Brain Ia antigens have a bone marrow origin. Immunogenetics, 1983, 17, 295-301.	1.2	40
286	Ia antigens on non-lymphoid tissues their origins and functions. Trends in Immunology, 1982, 3, 339-342.	7.5	30
287	Methods for Detection of Antigen-Specific T Cells by Enzyme-Linked Immunospot Assay (ELISPOT). , 0, , 290-295.		0